This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One of the biggest problems with a system that directs medical research towards profits rather than needs is that R&D funding is channelled to those products that can make pharma companies the most money. The best prospects are drugs targeted at patients who are high-value and who will use the drugs long term.
“The ability to predict dissolution curves based on tablet structure, and vice versa, holds promising prospects for tablet design and the application of 3D printing in pharmaceuticals”, the authors explained. This paper is published in PharmaceuticalResearch.
But what happens when that in-person meeting is no longer a viable option for your prospect? Bearing the brunt of these COVID19 restrictions, pharmaceutical reps have had a hard time getting in the door to make sales, and their employers have noticed: Limited In-Person Access To HCPs.
The UK also faces similar regulatory challenges as some public health officials and drug regulators are slow to collaborate with pharmaceuticalresearchers on aging-related work. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Pharmaceuticalresearch has long relied on non-human primate models for early-stage discoveries, but their use continues to cause controversy. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content